Top in allergy/asthma: Sublingual immunotherapy for children; asthma increases sick days
Click Here to Manage Email Alerts
Sublingual immunotherapy for house dust mites improved allergic rhinitis symptoms over a 1-year period among children aged 1 to 4 years, according to results from an open-label study..
“There have been few studies of SLIT at younger ages,” Koki Sasamoto,PhD, department of allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital in Japan, told Healio. “However, this study demonstrates that when younger patients with allergic rhinitis undergo 1 year of mite SLIT, not only are their clinical symptoms improved, but their specific IgE, IgG4 and IgE-block factor levels are similar to those of school-aged children and adults.”
It was the top story in allergy/asthma last week.
In another top story, researchers reported an association between asthma and increased work absences and loss of productivity.
They also found a greater prevalence of sickness absence among study participants with both overweight and asthma.
Read these and more top stories in allergy/asthma below:
Sublingual immunotherapy effective for young children with allergic rhinitis
Sublingual immunotherapy for house dust mite allergy improved allergic rhinitis symptoms among children aged 1 to 4 years over 12 months, according to a study published in Pediatric Allergy and Immunology. Read more.
Asthma disrupts work productivity, leads to more sick days
Asthma is associated with increased work absences and loss of productivity, according to a study in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Air pollution increases risks for respiratory ED visits, hospitalizations
Air pollution increased the risk for ED visits and hospitalizations due to asthma and other respiratory diseases, results from a poster presented at ERS Congress 2024 revealed. Read more.
Food allergy prevalence doubled in Japan from 2010 to 2019
The prevalence of food allergy surged between 2010 and 2019 in Japan, increasing 1.7 times among children aged 6 years and younger, according to a study in Pediatric Allergy and Immunology. Read more.
Depemokimab reduces severe asthma exacerbations by half with twice-yearly treatment
Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European Respiratory Society International Congress. Read more.